-

Palleon Pharmaceuticals Announces Late-Breaking Oral Presentation on HLX79/E-602 in Autoimmune Disease at the 2026 American Society of Nephrology (ASN) Kidney Week

– Presentation will provide an update on HLX79/E-602, a first-in-class human sialidase enzyme therapeutic, in patients with membranous nephropathy –

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing novel therapeutics for autoimmunity and cancer, will deliver a late-breaking oral presentation at the 2026 American Society of Nephrology (ASN) Kidney Week, taking place October 21-25 in Denver, Colorado. Palleon’s presentation will take place on Friday, October 23.

Details of Palleon’s Presentation:

American Society of Nephrology (ASN) Kidney Week

Title: HLX79 (E-602) Plus Rituximab Produces Fast and Durable Responses in Patients with Membranous Nephropathy
Oral Presentation Date and Time: Friday, October 23 from 11:00 to 11:15 AM MDT, Bluebird Ballroom; presented by Brad Rovin, M.D., Director, Division of Nephrology at The Ohio State University Wexner Medical Center

The presentation will be made available on the Glycobiology Education section of Palleon Pharmaceuticals’ website.

About Palleon Pharmaceuticals
Palleon Pharmaceuticals is a clinical-stage biotechnology company pioneering glycan editing, a new approach to immune modulation in autoimmune disease and cancer. Co-founded on the glycobiology research of Carolyn Bertozzi (2022 Nobel Laureate in Chemistry), Palleon’s pipeline includes E-602 (Phase 2, membranous nephropathy) and E-688/HLX316 (Phase 1, advanced solid tumors). www.palleonpharma.com

Contacts

Media
Lauren Crociati
Ten Bridge Communications
lcrociati@tenbridgecommunications.com

Palleon Pharmaceuticals


Release Versions

Contacts

Media
Lauren Crociati
Ten Bridge Communications
lcrociati@tenbridgecommunications.com

More News From Palleon Pharmaceuticals

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ACR Convergence 2026

WATERTOWN, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing glycan editing therapeutics for autoimmune disease and cancer, today announced early proof-of-concept data for its first-in-class sialidase-Fc fusion protein HLX79/E-602 (efgitasialase alfa) in primary membranous nephropathy (pMN). The results were presented in an oral session at the American College of Rheumatology (ACR) Convergence 2026 in Orlando. Palleon’s partner, Shanghai Henlius...

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026

WATERTOWN, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing glycan editing therapeutics for autoimmune disease and cancer, today announced Phase 2 results for HLX79/E-602 (efgitasialase alfa), a first-in-class sialidase-Fc fusion protein, in primary membranous nephropathy (pMN). The data were presented today in a late-breaking oral session at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver. The randomized Phase 2 trial (NCT07...

Palleon Pharmaceuticals Announces Oral Presentation of Interim Phase 2 trial data for HLX79/E-602 in Membranous Nephropathy at the 2026 American College of Rheumatology (ACR) Convergence

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing novel therapeutics for autoimmunity and cancer, will deliver an oral presentation at the 2026 American College of Rheumatology (ACR) Convergence, taking place November 6-11 in Orlando, Florida. Palleon's presentation will take place on Wednesday, November 11. Details of Palleon's Presentation: American College of Rheumatology (ACR) Convergence Title: Rapid and deep clinical responses to H...
Back to Newsroom